AbbVie beats Q3 expectations, lifts full-year EPS outlook as immunology and neuroscience drive growth

AbbVie reported third-quarter results that exceeded analysts' sales and earnings per share forecasts.

The company posted $17.4 billion in revenue, driven largely by its immunology franchise which generated $9.17 billion, a 16 percent year-over-year increase, and continued growth in its neuroscience segment.

Based on the beat, AbbVie raised its full-year EPS guidance to a range of $13.95-$13.99 and said it has capacity for additional bolt-on acquisitions, preferring smaller deals to another large merger.